Challenging and Changing Times

Times are undoubtedly tough for VCs investing in life sciences. Exits are few and far between. The public markets remain closed and, in terms of trade sales of VC-backed private pharma/biotech companies during H1/09, HBM Partners report that both the number and volume of transactions reached new lows (Read HBM’s survey here). The market is not however an excuse for poor returns and well-chosen, well-managed investments continue to return significant value to portfolios.

In order to deliver the returns promised to LPs, it has never been more critical to be able to source, diligence and exit investments on a global basis.

Biolauncher has the operational expertise to help investors diligence, develop and find commercial partners for their investments. Our information, global networks and industry knowledge are powerful resources to draw upon to maximize your returns. We have worked with a range of VC and private equity groups to provide scientific, operational and market input into investment and portfolio decision making.

In addition to a wide network of contacts in the investment community, Rowan is a member of the UK advisory board for Astia and chairs its UK Life Science subcommittee:

Astia is a global network of entrepreneurs, advisors and investors that is committed to building women leaders and accelerating the funding and growth of high-potential, high-growth, women-led startups.

Astia Client companies have raised over $500M since 2002 (including 5 raises since the start of 2010) and have achieved 13 exits.